As high levels of proNGF and neuroserpin have been found in both CSF and plasma, reflecting the brain’s NGF metabolic dysfunction [95,96,100,105,106,110,112,162,163], it is worth considering the possibility that these NGF metabolism-based CSF and plasma biomarkers might assist in the early AD diagnosis. This evidence concerns the gene SERPINI1 and Alzheimer disease.